RxDoctor Payments Data

Beverly Calkins, MD

Internal Medicine · Roseville, CANPI 1639123722

Payments from drug & device makers

$917in general payments, 2019–2025

Across 36 payments — averaging $25.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$195
  • Exact Sciences$160
  • Lilly USA, LLC$102
  • Johnson & Johnson$97
  • GSK$67
  • Azurity Pharmaceuticals, Inc.$62
  • plus $233 from 7 others

What the payments were for

  • Food & beverage$917100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$917 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$186,350
Medicare patients
354
Services billed
6,161

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban73$56,386
XareltoRivaroxaban39$38,413
JanuviaSitagliptin Phosphate26$29,873
OzempicSemaglutide24$27,192
RybelsusSemaglutide21$26,415
JardianceEmpagliflozin18$25,565
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$24,464
MounjaroTirzepatide21$23,782
TrulicityDulaglutide11$16,388
EntrestoSacubitril/Valsartan11$11,398
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$6,184
Levothyroxine Sodium440$5,459
Losartan Potassium390$5,282
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam32$4,403
Atorvastatin Calcium317$4,337

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$195$56,38673 claims
Novo NordiskOzempic, Rybelsus$51$53,60745 claims
Lilly USA, LLCMounjaro, Trulicity$102$40,17032 claims
Johnson & JohnsonXarelto$97$38,41339 claims
Boehringer IngelheimJardiance, Stiolto Respimat$46$31,74930 claims
GSKTrelegy Ellipta$67$24,46435 claims
NovartisEntresto$21$11,39811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Roseville

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →